| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | 0.037 | 0.2 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | -0.061 | 0.2 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | 0.08 | 0.2 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.042 | 0.3 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.3 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | -0.2 | 0.3 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |